Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Adalimumab (Humira®) - SMC 1143/16 - In progress. (Indication: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy).

Alirocumab (Praluent®) - SMC 1147/16 - In progress. (Indication: for specialist use only in adults with primary hypercholesterolaemia who are at high cardiovascular risk).

Bevacizumab (Avastin®) - SMC 1135/16 - In progress. (Indication: for use in combination with paclitaxel and cisplatin in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix).

Bortezomib (Velcade®) - SMC 1075/15 - In progress (Indication: for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation).

Brivaracetam (Briviact®) - SMC 1160/16 - Fomulary Group advice will be published by 5th October 2016. (Indication: for adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with refractory epilepsy).

Calcipotriol/betamethasone (Enstilar®) - SMC 1182/16 Fomulary Group advice will be published by 5th October 2016. (Indication: for topical treatment of psoriasis vulgaris in adults).

Dasatinib (Sprycel®) - SMC 370/07 - Fomulary Group advice will be published by 5th October 2016.  (Indication: for the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate).

Dasatinib (Sprycel®) - SMC 1170/16 Fomulary Group advice will be published by 5th October 2016. (Indication: for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase).

Fosfomycin trometamol (Monuril®) - SMC 1163/16 - Fomulary Group advice will be published by 5th October 2016. (Indication: - Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females.
- Prophylaxis in diagnostic and surgical transurethral procedures).

Idarucizumab (Praxbind®) - SMC 1178/16 - Fomulary Group advice will be published by 5th October 2016. (Indication: idarucizumab is a specific reversal agent for dabigatran and is indicated in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding).

Mepolizumab (Nucala®) - SMC 1149/16Fomulary Group advice will be published by 5th October 2016. (Indication: as an add-on treatment for severe refractory eosinophilic asthma in adult patients).

Nivolumab (Opdivo®) - SMC 1120/16 - In progress. (Indication: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab).

Nivolumab (Opdivo®) - SMC 1144/16 - In progress. (Indication: for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults).

Ofatumumab (Arzerra®) - SMC 1037/15 -  In progress. (Indication: in combination with chlorambucil for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy).

Paliperidone palmitate (Trevicta®) - SMC 1181/16 - Fomulary Group advice will be published by 5th October 2016. (Indication: paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product).

Secukinumab (Cosentyx®) - SMC 1167/16Fomulary Group advice will be published by 5th October 2016. (Indication: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients whose disease has not responded to adequate trials of at least two standard DMARDs either individually or in combination).

Tolvaptan (Jinarc®) - SMC 1114/15 - In progress. (Indication: to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease).

Trametinib (Mekinist®) - SMC 1161/16 -Fomulary Group advice will be published by 5th October 2016. (Indication: in combination with dabrafenib for the first line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation).

Publication schedule

This web page is updated monthly, within 7 working days of publication of Scottish Medicines Consortium advice.

END